OnePin Peptide Library · Muscle
GDF-8 (Myostatin)
Myostatin · Growth Differentiation Factor 8
GDF-8 (Growth Differentiation Factor 8), also known as Myostatin, is the biological molecule that NEGATIVELY regulates skeletal muscle growth. It is a member of the TGF-β superfamily, secreted by skeletal muscle cells, and acts in an autocrine/paracrine fashion to suppress muscle protein synthesis and limit muscle hypertrophy. Genetic loss-of-function in myostatin produces dramatic muscle hypertrophy (Belgian Blue cattle, the well-known 'mighty mouse' transgenic mouse line, and rare human cases of myostatin-related muscular hypertrophy).
GDF-8 / Myostatin is the muscle-INHIBITING factor itself. This entry is provided for catalog completeness. Users seeking muscle hypertrophy should use myostatin INHIBITORS (Follistatin 344, ACE-031, anti-myostatin antibodies in clinical trials) rather than administering myostatin itself.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
GDF-8 / Myostatin binds activin receptor type IIB (ActRIIB) on skeletal muscle cells, then recruits ALK4 / ALK5 type I receptors to form an active receptor complex. Receptor activation triggers Smad2/Smad3 phosphorylation and nuclear translocation, suppressing transcription of muscle hypertrophy genes (MyoD, myogenin) and activating muscle atrophy programs (FoxO-driven ubiquitin ligase expression).
Muscle Mass Negative Regulation
Genetic myostatin knockout produces 2-3x muscle mass increase in mice; Belgian Blue cattle homozygous for myostatin loss-of-function have characteristic 'double-muscled' phenotype. Established as the dominant negative regulator of skeletal muscle mass.
Activin Receptor Pathway
Myostatin shares receptors with related TGF-β family members (activin A, GDF-11). Therapeutic inhibitors that target ActRIIB (e.g. ACE-031) capture multiple ligands simultaneously, which produces broader effects than myostatin-specific inhibition (and broader off-target potential).
Smad Signaling
Smad2/3 nuclear translocation suppresses MyoD/myogenin transcription, blocking myoblast differentiation and limiting hypertrophy under loading stress.
Atrophy Programs
Beyond suppressing growth, myostatin also activates FoxO1/3-mediated transcription of atrogenes (MuRF1, atrogin-1) that drive muscle protein degradation - active atrophy signal at high concentrations.
Inhibitor Strategies
Therapeutic strategies INHIBIT myostatin via: (a) soluble receptor decoys (ACE-031, BMS-986089), (b) anti-myostatin antibodies (domagrozumab, landogrozumab, trevogrumab, taldefgrobep), (c) follistatin (endogenous antagonist binding myostatin and other ligands), (d) propeptide-based inhibitors. None of these have achieved FDA approval as of this writing.
CONFLICT WITH USER GOALS
Administering exogenous GDF-8 / myostatin would SUPPRESS muscle growth - opposite of typical fitness/recovery use of peptides. This entry exists for catalog completeness; intentional administration is contradictory to typical user goals.
What to expect
Reference protein - timeline does not apply to therapeutic context.
N/A
N/A
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Not typically administered - side effect profile is theoretical only
Less common & notes
- Theoretical chronic exposure to exogenous myostatin would produce muscle catabolism, reduced exercise tolerance, and potentially metabolic dysregulation.
- There is no clinical literature on intentional exogenous myostatin administration in humans because there is no clinical rationale for it.
Pharmacokinetics
Storage. If encountered as a reference protein: refrigerate (2-8°C / 36-46°F) or freeze (-20°C). Lyophilized form is more stable than reconstituted. Reconstituted protein typically usable for 7-14 days refrigerated. Reference proteins should be handled per manufacturer's certificate of analysis specifications. Avoid freeze-thaw cycles.
Regulatory status
GDF-8 / Myostatin itself has no FDA-approved therapeutic use. It is sold as a reference / research protein for laboratory use (assay standards for myostatin inhibitor development, ELISA controls, etc.) but not for human administration. Therapeutic development in this pathway focuses on INHIBITION of myostatin via various antagonist strategies. WADA's class S2 / muscle-modulator section indirectly relates to this molecule's biology but the prohibition targets myostatin INHIBITORS rather than the protein itself.
Put it to work
Calculate, log & track
Open GDF-8 (Myostatin) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open GDF-8 (Myostatin) in the app →Go deeper
The guide & community
The complete GDF-8 (Myostatin) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗